Growth Hormone FDA Approved

Tesamorelin

A growth hormone-releasing hormone analog approved in the United States for reducing excess abdominal fat in certain adults with HIV-associated lipodystrophy.

GHRHFDA ApprovedBody CompositionHIV Lipodystrophy

Also referenced as: Egrifta, Egrifta SV

Also appears in: Muscle Growth

Price compare
124 tracked offers across 124 vendors · 18 dosages
Best trust-adjusted value: Crush Research · Strong trust · $3.14/mg
From
$3.14/mg
Status
FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Category
Growth Hormone

Primary lane: Growth Hormone. Also surfaces under Muscle Growth for browsing and discovery.

Aliases
2

Egrifta, Egrifta SV

Signal depth
High

FDA label signal · 24 trials · 93 PubMed results

Established
Research evidence

Tesamorelin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Tesamorelin has 9 name-matched clinical trials (highest phase: Phase 4) and 93 PubMed-indexed publications and holds an FDA drug label. 3 trials have posted results.

FAERS (approved drug): 7
Human data
Approved drug
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
High-impact
PHASE4 · Randomized Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® PHASE2 · Randomized Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) PHASE2 · Randomized Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV The Journal of Clinical Endocrinology & Metabolism · 96 citations Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data JAMA · 87 citations Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation The Lancet HIV · 82 citations Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What tesamorelin is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone. In the United States, it is best known through Egrifta and Egrifta SV, which are FDA-approved for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.

Why it matters on this site

Tesamorelin is useful because it reminds people that not every peptide conversation is really about gray-market research compounds. Some peptides have narrow, specific, fully regulated indications that should not be blurred into broader enhancement or physique chatter.

Regulatory context

FDA labeling for tesamorelin products states the approved indication as reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy:

Practical reading note

Tesamorelin gets discussed far outside its actual approved use. That makes it a good test case for how to read peptide claims carefully:

  • approved indication does not equal general-purpose body-composition approval
  • mechanism does not equal outcome in every population
  • community enthusiasm does not replace label language

Why we include it

On PeptideBenchmark, tesamorelin is less about trend-chasing and more about helping readers separate:

  • FDA-approved peptide medicines
  • investigational drugs
  • and research-market compounds discussed under the same broad “peptide” umbrella